Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
CARE and JUSTICE
JUSTICE Clinical Trial Janus kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)
Brief Description
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
Trial Physician / Study Coordinator
Maurice Smith
EmailSite Name
Duke University
300 North Duke Street, Durham, NC 27701
Sponsor
NIAHD
Study Drug
Baricitinib
Estimated enrollment
75 patients
Estimated end date
2026
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
CARE and JUSTICE
JUSTICE Clinical Trial Janus kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)
Brief Description
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
Trial is for people with
Focal Segmental Glomerulosclerosis or clinically diagnosed HTN-CKD
Study Goal
The goal of JUSTICE clinical trial is to determine whether inhibition of APOL1 protein production by baricitinib would slow down progression of APOL1-mediated kidney disease and reduce spillage of protein in the urine.
What is involved for the Patient?
Participants will be randomized to receive baricitinib or placebo control. Urine and a small blood sample will be collected monthly to monitor kidney function. Participants will be followed for 6 months. Participants will receive compensation each month.